• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Current Evidence on the Usefulness of Potential Therapies in the Prevention of COPD Exacerbations: Beyond the Use of Bronchodilator Therapy and Inhaled Corticosteroids.预防慢性阻塞性肺疾病(COPD)急性加重的潜在疗法有效性的当前证据:超越支气管扩张剂疗法和吸入性糖皮质激素的应用
Open Respir Arch. 2025 May 7;7(2):100438. doi: 10.1016/j.opresp.2025.100438. eCollection 2025 Apr-Jun.
2
Overuse of long-acting β-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.慢性阻塞性肺疾病患者长效β受体激动剂/吸入性糖皮质激素的过度使用:是时候重新思考处方模式了。
Postgrad Med. 2023 Nov;135(8):784-802. doi: 10.1080/00325481.2023.2284650. Epub 2024 Jan 10.
3
Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.低剂量茶碱口服联合吸入皮质激素治疗慢性阻塞性肺疾病且有加重高风险的患者:一项 RCT 研究。
Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370.
4
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范(2023年)]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
5
Guideline for the management of chronic obstructive pulmonary disease--2011 update.慢性阻塞性肺疾病管理指南——2011 年更新版。
S Afr Med J. 2011 Jan;101(1 Pt 2):63-73.
6
Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.慢性阻塞性肺疾病(COPD)管理指南:2004年修订版
S Afr Med J. 2004 Jul;94(7 Pt 2):559-75.
7
Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.慢性阻塞性肺疾病:对有反复症状的患者有用的药物。
Prescrire Int. 2016 Nov;25(176):272-277.
8
Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.老年人慢性阻塞性肺疾病急性加重的管理:已发表证据的评估
Drugs Aging. 2007;24(4):303-24. doi: 10.2165/00002512-200724040-00004.
9
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.双重联合疗法与长效支气管扩张剂单药治疗慢性阻塞性肺疾病(COPD)的疗效比较:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2018 Dec 3;12(12):CD012620. doi: 10.1002/14651858.CD012620.pub2.
10
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.

本文引用的文献

1
Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.慢性阻塞性肺疾病的生物治疗:随机对照试验的系统评价和网状Meta分析
COPD. 2025 Dec;22(1):2449889. doi: 10.1080/15412555.2025.2449889. Epub 2025 Jan 29.
2
Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.预防性抗生素在慢性阻塞性肺疾病中的疗效:一项系统评价
Antibiotics (Basel). 2024 Nov 21;13(12):1110. doi: 10.3390/antibiotics13121110.
3
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.特泽佩umab对比安慰剂治疗中重度至非常重度慢性阻塞性肺疾病成人患者的疗效和安全性(COURSE):一项随机、安慰剂对照的2a期试验
Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6.
4
Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.高剂量 N-乙酰半胱氨酸对轻中度 COPD 患者加重和肺功能的影响:一项双盲、平行分组、多中心随机临床试验。
Nat Commun. 2024 Sep 30;15(1):8468. doi: 10.1038/s41467-024-51079-1.
5
Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized control trials.益生菌治疗对慢性阻塞性肺疾病患者和动物的影响:系统评价和随机对照试验的荟萃分析。
Front Cell Infect Microbiol. 2024 Sep 11;14:1411222. doi: 10.3389/fcimb.2024.1411222. eCollection 2024.
6
Use of Sodium-glucose cotransporter 2 (SGLT 2) inhibitor is associated with reduced emergency room visits and hospitalizations in patients with Chronic obstructive pulmonary disease (COPD) and type 2 Diabetes Mellitus.钠-葡萄糖共转运蛋白 2(SGLT 2)抑制剂的使用与慢性阻塞性肺疾病(COPD)和 2 型糖尿病(T2DM)患者急诊就诊和住院次数减少相关。
Respir Med. 2024 Nov-Dec;234:107819. doi: 10.1016/j.rmed.2024.107819. Epub 2024 Sep 24.
7
Gut Microbiota Modulation in the Management of Chronic Obstructive Pulmonary Disease: A Literature Review.慢性阻塞性肺疾病管理中肠道微生物群的调节:文献综述
Cureus. 2024 Aug 14;16(8):e66875. doi: 10.7759/cureus.66875. eCollection 2024 Aug.
8
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.双重磷酸二酯酶3和4抑制剂恩昔芬净对中度至重度慢性阻塞性肺疾病患者急性加重率及风险的影响
Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27.
9
Diabetes mellitus with poor glycemic control is a risk factor for pneumonia in COPD.血糖控制不佳的糖尿病是慢性阻塞性肺疾病(COPD)患者发生肺炎的一个危险因素。
Respir Med Res. 2024 Nov;86:101135. doi: 10.1016/j.resmer.2024.101135. Epub 2024 Aug 7.
10
Long-Term Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease, a Multinational Observational Database Cohort Study.罗氟司特治疗慢性阻塞性肺疾病患者的长期安全性:一项多国观察性数据库队列研究。
Int J Chron Obstruct Pulmon Dis. 2024 Aug 21;19:1879-1892. doi: 10.2147/COPD.S465517. eCollection 2024.

预防慢性阻塞性肺疾病(COPD)急性加重的潜在疗法有效性的当前证据:超越支气管扩张剂疗法和吸入性糖皮质激素的应用

Current Evidence on the Usefulness of Potential Therapies in the Prevention of COPD Exacerbations: Beyond the Use of Bronchodilator Therapy and Inhaled Corticosteroids.

作者信息

Figueira-Gonçalves Juan Marco, Callejas-González Francisco Javier, Golpe Rafael, Máiz-Carro Luis, Marín-Oto Marta, de Miguel-Díez Javier, Loscertales-Vacas Guillermo Samuel, Tordera-Mora José María, Hurtado-Fuentes Álvaro

机构信息

Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Department of Respiratory Medicine, Albacete University Hospital Complex, Albacete, Spain.

出版信息

Open Respir Arch. 2025 May 7;7(2):100438. doi: 10.1016/j.opresp.2025.100438. eCollection 2025 Apr-Jun.

DOI:10.1016/j.opresp.2025.100438
PMID:40510241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12159216/
Abstract

Prevention of exacerbations is a key objective in chronic obstructive pulmonary disease (COPD) management. The adverse effects of an exacerbation include a negative impact on patient quality of life and symptoms, an accelerated rate of decline in lung function, hospital admissions, and increased mortality. Clinical guidelines related to COPD management recommend smoking cessation and inhaled therapy (bronchodilators with or without corticosteroids) as the mainstay for these patients. Apart from the above-mentioned treatment, other potential therapies, such as mucolytic agents, antibiotics (oral or inhaled), phosphodiesterase-4 inhibitors or vaccination, are available and have been shown to reduce the incidence of exacerbations. In this brief narrative review, we will examine the efficacy of various treatments for preventing COPD exacerbations, beyond the use of bronchodilator therapy and inhaled corticosteroids.

摘要

预防急性加重是慢性阻塞性肺疾病(COPD)管理的关键目标。急性加重的不良影响包括对患者生活质量和症状产生负面影响、肺功能下降加速、住院以及死亡率增加。与COPD管理相关的临床指南推荐戒烟和吸入治疗(使用或不使用皮质类固醇的支气管扩张剂)作为这些患者的主要治疗方法。除上述治疗外,其他潜在疗法,如黏液溶解剂、抗生素(口服或吸入)、磷酸二酯酶-4抑制剂或疫苗接种,也可供使用,并已证明可降低急性加重的发生率。在这篇简短的叙述性综述中,我们将探讨除使用支气管扩张剂治疗和吸入皮质类固醇之外的各种预防COPD急性加重治疗方法的疗效。